MassBio Board of Directors

Glenn Batchelder
Chairman

Glenn Batchelder is a co-founder and board member of Civitas Therapeutics, a pulmonary delivery company with a lead program for treating Parkinson’s disease. Mr. Batchelder served as the CEO for the first four years of the company’s existence leading the acquisition of the platform, the financing and advancing the Parkinson’s program up to the final stages of development.  Prior to Civitas, he was the founding CEO of BIND Therapeutics (BIND), a leading nanotherapeutics company.  Prior to BIND, Mr. Batchelder was the initial CEO of Acceleron Pharma (XLRN) an oncology and supportive care biotherapeutics company.   Prior to Acceleron, Mr. Batchelder was Senior Vice President of Operations at Millennium Pharmaceuticals where he played an integral leadership role in the launch of VELCADE® and was responsible for the commercial supply chain and technical operations for INTEGRILIN®.   Mr. Batchelder received a BS in Chemical Engineering from Lehigh University.

Dr. Abbie Celniker, Ph.D.
Vice Chairman

Abbie Celniker, Ph.D is the CEO of Eleven Biotherapeutics, a biopharmaceutical company focused on engineering and developing innovative protein-based therapies.  Dr. Celniker has been in the biotechnology and pharmaceutical industry for over 25 years where she has worked in small and mid-sized biotechnology companies as well as mid-sized and large pharmaceutical companies.  Prior to Eleven, Abbie was head of Translational Medicine at Alexion Pharmaceuticals by way of the acquisition of Taligen Therapeutics where she was the President and CEO.  Prior to joining Taligen, Dr. Celniker was the Global Head of Novartis Biologics where she was responsible for the oversight of the discovery and development of the Novartis biologics pipeline.  Dr. Celniker has also been the Global Head of the Program Office for the Novartis Institutes for Biomedical Research (NIBR) where she was responsible for the global integration and oversight of the Novartis Discovery Portfolio.  In a previous role at Millennium Pharmaceuticals, Dr. Celniker led the pipeline portfolio review committee and headed Development Project Management and Pharmaceutical Sciences.  Prior to Millennium, Dr. Celniker was at Wyeth, where she was assistant vice president for predevelopment and biopharmaceutical core technologies. She has previously held positions at Genetics Institute, Genentech Inc. and the University of Arizona Cancer Center.  Dr. Celniker has a bachelor's degree in biology from the University of California at San Diego and earned her Ph.D. in molecular biology at the University of Arizona.

Michael O'Hara
Treasurer

Mr. O'Hara is a partner and leads the life sciences audit practice of Deloitte in Boston.  In addition to serving many life sciences companies in various capacities, Mr. O'Hara also serves as audit partner for publicly traded and private life sciences companies and a large integrated healthcare system, and therefore has a comprehensive understanding of the healthcare industry.  Mr. O'Hara has been involved in several IPOs, mergers and acquisitions engagements, financial forecasting projects, and value-added projects on accounting and financial reporting.  Mr. O'Hara has assisted his clients through product launches and rapid growth phases including advising on financial and operational infrastructure challenges.  In addition to his role as Treasurer of the Massachusetts Biotechnology Council, Mr. O'Hara is a member of the Board of Directors of the Massachusetts Medical Device Industry Council (MassMEDIC) and the Medfield Youth Hockey Association.  He is also a member of the AICPA and the Massachusetts Society of CPAs and is an adjunct professor of accounting and auditing at Boston College.

Mr. O'Hara received his BA from Oneonta State University and his MBA from Boston College.  He lives in Medfield, MA with his wife Maryclare, son Liam and daughter Maeve.

David Lucchino
Clerk

Mr. Lucchino is Co-Founder and Chief Executive Officer of Semprus BioScienecs. Mr. Lucchino co-founded Semprus BioSciences, a biomedical spinout from MIT’s famed Langer Lab in 2007. Under his stewardship, the company has grown from two to 30 employees and secured $28.5M in venture capital financing. The company is preparing to commercialize its first product: a peripherally inserted central catheter called the Nylus™ PICC with Semprus Sustain™ Technology.

Semprus BioSciences has introduced its platform – the Semprus Sustain™ Technology – that organizes, manages and harnesses water molecules. This technology simultaneously inhibits both bacteria biofilm formation and blood clotting on medical devices while establishing a polymer matrix that can provide next-generation drug delivery applications. The company is providing a preventative medicine solution that targets well known clinical complications at the confluence of medical devices and human biology. The company recently submitted its first 510(k) application to the FDA and is continuing to develop a pipeline of medical products.

Prior to co-founding Semprus, Mr. Lucchino was a Senior Associate at Polaris Venture Partners, a $3 billion venture capital fund based in Boston. He also co-founded and served as Managing Director of LaunchCyte, an investment firm that specializes in acquiring and developing University based biomedical intellectual property. One of its portfolio companies, Knopp Neurosciences, recently entered into an exclusive $345 million license agreement with Biogen Idec. Mr. Lucchino began his career as a technology marketing executive in New York City. He is a trustee of Mt. Auburn Hospital, a Harvard Medical School facility, and also sits on the board of AdvaMed (Advanced Medical Technology Association), the world’s leading medical device trade association. He earned an MBA from MIT’s Sloan School of Management, an MS from Syracuse University’s Newhouse School of Public Communications and a BA from Denison University.

Geoff MacKay
Immediate Past Chairman

Geoff MacKay has served as President & CEO of Organogenesis since December 2003. Mr. MacKay provides Organogenesis with significant global, commercial experience spanning the pharmaceutical and biotechnology sectors. Mr. MacKay has held numerous leadership positions within Novartis AG in roles such as Vice-President and Business Unit Head, Transplantation and Immunology at Novartis Canada, Vice-President of Tissue-Engineering in Novartis USA, Head of Global Sales Immunology and Transplantation based in Basel, Switzerland, and prior to that as Sales and Marketing Manager of Novartis Biotech Europe. Mr. MacKay has been specifically involved in the emerging field of regenerative medicine for the last decade. He currently serves as Chairman of the Board of Directors for the Massachusetts Biotechnology Council (MassBio), and as Chair of the Alliance for Regenerative Medicine (ARM).

Caren Arnstein

Caren Arnstein is Senior Vice President and Head of Communications for Genzyme, a Sanofi company, one of world’s leading biotechnology companies.  As part of the executive leadership team, Caren oversees Genzyme’s global Corporate Communications, State and local Public Affairs and Community Relations functions.  Under her leadership, Genzyme has built a positive reputation as an innovative and socially responsible company – committed to improving the lives of people with debilitating diseases.  

Caren provides strategic direction for external and internal communications programs, including media relations, leadership communications and issues management.  In her 16 years with Genzyme, she has lead major initiatives for product launches, mergers and acquisitions, shareholder activism, and product supply challenges.  Caren works closely with government relations colleagues to help communicate Genzyme’s position on the many public policy issues affecting the life sciences industry.    

In addition, Caren oversees global corporate citizenship programs, supporting employee-initiated volunteer activities in our communities.  She leads the company’s charitable grants advisory board and community relations programs focused on addressing science education and health needs.  She also serves on the State Board for the March of Dimes and the Greater Boston Chamber of Commerce Board of Directors.  

Caren has more than 25 years of communications experience in the life sciences.  Prior to joining Genzyme in 1995, she worked in the environmental services field as a consultant to leading companies and communities on a broad range of environmental communication projects.  Caren earned an M.S. in Communication Management from Simmons College and a B.S. in Environmental Science from the University of Massachusetts at Amherst.   

Mark R. Bamforth

Mr. Bamforth is the President and CEO of Gallus Biopharmaceuticals, a Contract Manufacturing company formed in 2010 with the acquisition of an existing, approved bulk biologics manufacturing site from a “big pharma” company. Prior to Gallus, Mark was the SVP, Corporate Operations and Pharmaceuticals at Genyzme. He was responsible for Genzyme's global manufacturing operations and strategic capacity planning as well as the Pharmaceuticals business. Prior to 2000, Mr. Bamforth ran Genzyme's United Kingdom operations. Before joining Genzyme, Mr. Bamforth worked as a drilling engineer in the North Sea offshore oil industry and then as a chemical engineer in the whisky industry in Scotland. Mr. Bamforth has an M.B.A. from Henley Business School and a B.Sc. Honours in chemical engineering from Strathclyde University.

Margaret Chu-Moyer, Ph.D.

Margaret Chu-Moyer is Executive Director Research, Amgen, Inc. and Site Head, Amgen Massachusetts.  Margaret joined Amgen’s Chemistry Research and Development group in 2009 as head of medicinal chemistry for the Cambridge site.

Prior to joining Amgen, Margaret served in a number of positions of increasing responsibility at Pfizer Global Research and Development in Groton, CT.  Over the course of her 16-year tenure in the Cardiovascular, Metabolic and Endocrine Diseases therapeutic area, she was responsible for leading medicinal chemistry drug discovery research in diabetes, obesity, osteoporosis and frailty, resulting in over a dozen development candidates.  She also led the CVMED Hit-to-Lead/Lead Generation Group.  Margaret currently serves on the Broad/Harvard-Chemical Methodology & Library Development External Advisory Board and was recognized as one of Mass High Tech’s 2011 Women to Watch.

Margaret received her BS in Chemistry from the University of California, Berkeley and obtained her Ph.D. in Organic Chemistry from Yale University where her research focused on natural products total synthesis.

Geoffrey F. Cox, Ph.D.

Dr. Cox is a Partner at Red Sky Partners LLC, a firm providing corporate strategy, business development and virtual and transition operating management services to clients in the biotechnology and biopharmaceuticals industry. He has over 35 years of pharmaceutical and biotechnology experience in a broad range of senior management positions in operations management, as a CEO and as a member of the board of public and private companies.

In 1984, Dr. Cox joined Genzyme Corporation in the U.K. and then, in 1988, became Senior Vice President, Operations, in the U.S. Dr. Cox later became Executive Vice President responsible for operations and the pharmaceutical, diagnostic and genetics business units of Genzyme. Prior to joining Genzyme, Dr. Cox was General Manager of the U.K. manufacturing operations for  Gist-Brocades.

In 1997, Dr. Cox became Chairman and CEO of Aronex Pharmaceuticals, Inc., based in The Woodlands, Texas, and subsequently, in July 2001, he became Chairman, President and CEO of GTC Biotherapeutics, Inc., based in Framingham, Massachusetts, a position he held until June 2010.

Dr. Cox is non-executive Chairman of the Board of Nabi Biopharmaceuticals and a Director of Gallus Biopharmaceuticals. He also served for a number of years on the Board of the Biotechnology Industry Organization and also as a member of their Emerging Companies Section and Healthcare Section Governing Body Committees.

Dr. Cox received a B.Sc. (Hons) in Biochemistry from the University of Birmingham, U.K. and a Ph.D. in Biochemistry from the University of East Anglia, U.K.

Jeffrey Elton

Jeff Elton has 20 years of experience as a consultant, executive, and investor in the biopharmaceutical and biomedical sectors. He is the founder, vice chairman, and CEO of KEW Group, LLC a Personalized Medicine and oncology care delivery company; faculty member at Boston University School of Management; and advisor to a number of mature and early stage life science companies.

Prior to founding KEW Group, Mr. Elton was Senior Vice President of Strategy and Global Chief Operating Officer at Novartis Institutes of BioMedical Research, Inc. (NIBR) in Cambridge, MA.  He led the definition of disease area, research partnership, and global operations strategies. Mr. Elton oversaw all NIBR operations in the US, Europe, and Asia, responsible for Finance, Human Resources, Legal, Patents, Business Development, Information Technology, Research Operations, Facilities, and Strategy & Operations, Security, and Communications.  Before Novartis, Mr. Elton was a partner with McKinsey & Company PMP and Intellectual Property/Strategy practices, and has been published in Harvard Business Review, McKinsey Quarterly, Radiology, In Vivo and other noted publications.

Mr. Elton is a member of the advisory board of the Harvard Medical School - Partners Healthcare Center for Genetics and Genomics; a member of the advisory board of the Massachusetts Life Sciences Start Up Initiative; executive committee and board member of the Elizabeth Glaser Pediatric AIDS Foundation; and overseer of the DeCordova Museum of Art.  He holds a Ph.D. in Business Economics and Marketing and an M.B.A. in Finance and Statistics from the University of Chicago Graduate School of Business.

Scott Gillis

Scott H. Gillis is CEO of Onsite Therapeutics, Inc. and also an independent consultant with more than 37 years' experience in the pharmaceutical and medical device industry in capacities ranging from sales and marketing positions to general management. He has extensive experience in the fields of dermatology, anti-infective, cardiovascular, oncology, psychiatric, orthopedic, dental and wound care products. His experience includes the advancement of medical ideas from research and development to commercial products, securing financing, and negotiating sales, marketing and distribution partnerships with major healthcare corporations.

Prior to becoming CEO of OnSite Therapeutics, Inc. and consulting, Mr. Gillis served as President and CEO of NUCRYST Pharmaceuticals, Inc. for 8 years. He took NUCRYST public on the NASDAQ and TSX in 2005. Mr. Gillis also served as President and CEO of Li Medical, a private medical device company, for 5 years. Prior to Li Medical, Mr. Gillis spent 15 years at Bristol-Myers Squibb where he worked in a number of divisions including Squibb, Westwood, Mead Johnson Pharmaceuticals, ConvaTec and Mead Johnson Oncology. At ConvaTec, he served as Vice President and General Manager of ConvaTec USA and later as Global Vice President, Wound and Skin Care.

A Boston native, Mr. Gillis has an MBA from Xavier University and a BA in Biology and Chemistry from Salem State College.

Steven C. Gilman, Ph.D.

Steven C. Gilman, Ph.D., is Executive Vice President, Research and Development and Chief Scientific Officer at Cubist Pharmaceuticals, Inc. Dr. Gilman joined Cubist in 2008 as Senior Vice President, Discovery and Non-clinical Development and Chief Scientific Officer.

Dr. Gilman has more than 25 years of drug research and development experience. Before joining Cubist, he was Chairman of the Board and Chief Executive Officer of ActivBiotics, Inc. While at ActivBiotics, Dr. Gilman led the transition of the organization from early research/academic stage to focus on advanced product development/commercialization. Previously he was Vice President and General Manager, Inflammation Franchise, Millennium Pharmaceuticals, Inc. Earlier in his career, Dr. Gilman was responsible for pharmaceutical research units at Pfizer, Sterling Winthrop, Cytogen Corporation and Wyeth Laboratories in areas including chronic inflammatory diseases, transplant rejection, autoimmune diseases and bacterial infections.

Dr. Gilman has a Ph.D. in Microbiology from Pennsylvania State University and completed his post doctoral training in the Department of Immunopathology at Scripps Clinic and Research Foundation in La Jolla, California.

Jose-Carlos Gutierrez-Ramos, Ph.D.

Dr. Gutierrez is Senior Vice President and head of the BioTherapeutics Research Group, which includes three Research Units (RUs), the global Pharmacokinetics, Dynamics and Metabolism - New Biological Entities (PDM-NBE) department, and the Global BioTherapeutic Technologies (GBT) department.

Prior to joining Pfizer, Dr. Gutierrez was SVP and Head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at GSK. Dr. Gutierrez built the iiCEDD as a global group of "drug hunters"  that included biologists, chemists, pharmacologists, protein scientists and clinicians who were responsible for the discovery of drugs in that space all the way to Phase IIa (POC).

Prior to GSK he served at AMGEN Mountain View as Site Head and CSO. Previous to the AMGEN acquisition of Avidia he was the SVP of R&D, where he led a significant effort of novel protein therapeutics for autoimmune disease. Before his AVIDIA appointment, he served as CSO of Peptimmune Inc. in Cambridge where he was responsible for the development of peptide based therapeutics for autoimmune disease, including MS and diabetes. Before Peptimmune, Dr. Gutierrez served as Vice President, Inflammation at Millennium Pharmaceuticals, where he built and led a group of more than 150 scientists.

Dr. Gutierrez was also a faculty member at the Genetics department of Harvard Medical School, where he led a research team at the Center for Blood Research. Before coming to the US, he was member of the Basel Institute for Immunology in Basel, Switzerland and a fellow at the Max-Plank for Immunbiologie in Freiburg, Germany. Dr. Gutierrez received his masters in Chemistry and his Ph.D. in Immunology from the Autonoma University of Madrid, Spain.

James Hoyes

James Hoyes is the President of EMD Serono, Inc. In this capacity, his responsibilities include driving the strategic direction of the US organization as well as managing the day to-day operations of the US affiliate of Merck KGaA, Darmstadt, Germany. As head of the US business, Mr. Hoyes is a member of several global management teams.

In his previous role as Chief Commercial Officer, he was responsible for business operations in the company’s key therapeutic areas of neurodegenerative disease, rheumatology, fertility and metabolic endocrinology, as well as Managed Care, Business Intelligence, Health Outcomes, Specialty Pharmacy and Commercial Operations.

Mr. Hoyes has also served as Executive Vice President, managing the operations of sales,
marketing, communications, call center operations, and medical affairs for the Neurology portfolio. He joined EMD Serono in February 2004 as Vice President of Marketing in Neurology.

Prior to EMD Serono, Mr. Hoyes gained experience in a variety of commercial roles of increasing responsibilities at Elan, Sanofi and Sterling Drug. Mr. Hoyes also has extensive experience working in a partnership environment (such as co-promotion and joint venture agreements) with other biopharmaceutical companies such as Pfizer, BMS, UCB and Wyeth.

Mr. Hoyes is a member of the Board of Directors of both The Pharmaceutical and Research
Manufacturers of America (PhRMA) and The Biotechnology Industry Organization (BIO).

Mr. Hoyes graduated from the Pennsylvania State University with a Bachelor of Science in Biology.

Edwin M.  Kania, Jr.

Mr. Kania is the Managing Partner and Chairman of Flagship Ventures. Prior to co-founding Flagship Ventures in 2000, he spent 15 years as Managing General Partner of OneLiberty Ventures and as General Partner at its predecessor firm, Morgan Holland Ventures. His direct investment experience covers over 100 companies. In addition, he has been intimately involved in the launch and development of more than a dozen companies as the founding and lead investor. Mr. Kania is currently a director of Aspect Medical Systems (Nasdaq: ASPM), EXACT Sciences (Nasdaq: EXAS), Acceleron Pharma, Interactive Supercomputing, INTIO, Parasol Therapeutics, Pervasis Therapeutics, TARIS Biomedical, Inc., TransMedics, and VisEn Medical. He is also a member of The Johhs Hopkins Medicine Alliance for Science and Technology Development Industry. He holds a degree in physics from Dartmouth College and an MBA from Harvard Business School.

Laurie Bartlett Keating

Mrs. Bartlett Keating serves as Senior Vice President and General Counsel at Millennium: The Takeda Oncology Company. Ms. Keating is responsible for setting the company's legal, intellectual property and corporate quality strategies and priorities.

Prior to joining Millennium, Ms. Keating was co-founder and first CEO of Hydra Biosciences, Inc., a venture backed biotech company focused on developing drugs targeting novel ion channels. After joining Millennium in 2004, Ms. Keating remained a member of the Board of Directors of Hydra through 2007. Prior to Hydra, Ms. Keating served as an executive at high growth technology companies, including serving as Senior Vice President, General Counsel and Secretary of Iomega Corporation, a data storage company, and Sybase, Inc., a software company that grew from a few hundred to 6,000 employees during Ms. Keating's tenure on the management team. Based on her leadership at Sybase, Ms. Keating was named as one of the 45 most influential in-house lawyers in the United States under the age of 45. Upon graduating from law school, Ms. Keating practiced law at McCutchen, Doyle, Brown and Enersen (now Bingham McCutchen) in San Francisco.

Ms. Keating has a Doctor of Jurisprudence from the University of California, Hastings College of the Law, and a Bachelor of Science in Economics from the University of California at Berkeley.

Mark Leuchtenberger

Mark Leuchtenberger joined Acusphere, Inc. as President and Chief Executive Officer in 2013, bringing experience in commercial operations, business development and preparing biopharmaceutical companies for product approval and commercialization.  Mr. Leuchtenberger most recently served as President, Chief Executive Officer and a member of the board of directors at Rib-X Pharmaceuticals (now Melinta) until its acquisition.  Prior to Rib-X, Mr. Leuchtenberger served as President and Chief Executive Officer of Targanta Therapeutics Corporation, where he led the company’s initial public offering in 2007 and its acquisition in 2009.  From 2006 to 2009 Mr. Leuchtenberger served as the President and Chief Executive Officer of Therion Biologics Corporation, a privately held cancer vaccine company.  Prior to Therion, Mr. Leuchtenberger was a senior officer at Biogen Idec Inc., where he led the Avonex® development and launch in the United States and subsequently managed North American and international commercial operations. Mr. Leuchtenberger received his M.B.A. from the Yale School of Management and his B.A. from Wake Forest University.  He is a director and past chairman of the Massachusetts Biotechnology Council Board of Directors and currently serves as a trustee for Beth Israel Deaconess Medical Center and Chairman of the Advisory Committee for the MassDevelopment Emerging Technology Fund.  He is a co-founder of Albor Biologics, Inc. and Alvos Therapeutics, Inc.

Lisa M. Olson, Ph.D.

Dr. Lisa Olson is Vice President, Immunology Research and ABC Site Head of AbbVie Bioresearch Center Inc. Dr. Lisa Olson is responsible for the oversight and strategic development of AbbVie's Immunology research  program, and is Site Head for the AbbVie Bioresearch Center in Worcester, MA.

Following a post-doctoral fellowship at the University of Chicago, Chicago, IL, Dr. Olson joined the faculty of  the OB/GYN Department, Washington University Medical School, St. Louis, MO. In 1998, Olson left  Washington University to lead the Women’s Health Program within the Nutrition Sector of Monsanto Corp.,  St. Louis, MO. Two years later, she joined the Arthritis and Inflammation Department at Pharmacia Corp, St.  Louis, MO which subsequently evolved into the Inflammation Department of Pfizer Corp, St. Louis, MO. Dr.  Olson joined AbbVie (formerly Abbott) in 2005 as Director, Pharmacology and has had roles of increasing  responsibility ever since. In 2008, she was promoted to Senior Director, Pharmacology and Discovery Safety,  Metabolism and Pharmokinetics and in 2010 became Divisional Vice President, Immunology Research. Dr.  Olson became Site Head of the AbbVie Bioresearch Center in 2012.

Dr. Olson received her Ph.D. degree at the University of Illinois, Urbana, IL in 1986. Dr. Olson has published over 30 peer reviewed articles in journals and has authored six patents. She currently serves on the Board of  Directors for the Massachusetts Biotechnology Council and is a Trustee for the Massachusetts Biomedical  Initiatives.

Deanna Petersen

Deanna Petersen joined Shire in 2009 as Vice President of Business Development for Shire Human Genetic Therapies (HGT).  Deanna is a broadly skilled senior executive with 15 years of leadership experience in strategic planning and global business development.  Deanna is a member of Shire HGT’s senior leadership team and is responsible for identifying, evaluating and negotiating business opportunities.  Prior to joining Shire, Deanna was a Vice President at Anitgenics Inc. and Coley Pharmaceutical Group.  Deanna is on the Board of Directors for American DG Energy and is Co-Chair of the Business Development Committee for the Massachusetts Biotechnology Association.  Deanna holds a Bachelor of Science in Biology from Iowa State University and a Master of Business Administration from The University of Iowa.

Alice Lin Pomponio

Alice Lin Pomponio is Head of Corporate Affairs—North America Science Affairs for AstraZeneca.  Her team works closely with scientific stakeholders in academia, government, and nonprofits to promote favorable external R&D environments and to proactively shape AstraZeneca’s global science policies.  Prior to joining AstraZeneca in 2012, Alice was Senior Director of Global Policy Programs at Genzyme Corporation where she focused on international innovation, health, and trade policy issues affecting patient access to biologics and orphan drugs.  Between 2000 and 2005 she served as Vice Consul and US Life Sciences and Healthcare Industry Advisor to the British Government with responsibility for US industry relations and strategic input into UK government life sciences initiatives.  She previously worked at US Office of Management and Budget (OMB) with responsibility for the US Department of Energy (DoE) Human Genome Program management review.  She conducted laboratory research at Viagene Inc and the MIT Whitehead Institute and has held product pricing and reimbursement roles at Genzyme.  Alice holds a Bachelor of Science in Biology from MIT and a Master’s in Public Policy from Harvard University. 

Steven Richter, Ph.D.

Dr. Richter is President & CEO at Microtest Laboratories Inc. With his expertise in Sterilization Sciences, Dr. Richter founded Microtest in 1984 after a 5-year career as a microbiologist at the U.S. Food & Drug Administration. Under his leadership, Microtest has provided the medical device, pharmaceutical, and biotechnology industries with premier testing and manufacturing support. Dr. Richter received a B.S. degree in Microbiology from the University of Massachusetts-Amherst, an M.S. degree Biological Sciences from the University of Massachusetts-Lowell, and a Ph.D. in Sterilization Sciences from Columbia Pacific University.

Amit K. Sachdev

Mr. Sachdev joined Vertex in July 2007 and currently serves as the Senior Vice President, Public Policy and Government Affairs. In this role, he leads the company's corporate communications, government affairs and public policy functions.

Mr. Sachdev came from Biotechnology Industry Organization (BIO) where he served as Executive Vice President, Health. At BIO, he was the senior executive responsible for managing BIO's health policy department and its Governing Board. Mr. Sachdev is the former Deputy Commissioner for Policy at the U.S. Food and Drug Administration (FDA) where he also held several other senior appointments from 2002 to 2005. At FDA, he oversaw the development of all FDA policies, regulations and legislation.

From 1998 to 2002, Mr. Sachdev served as Majority Counsel to the Committee on Energy and Commerce in the U.S. House of Representatives. From 1993 to 1997, Mr. Sachdev practiced law, first at the Chemical Manufacturers Association, and then with the law firm of Ropes and Gray. Mr. Sachdev received a B.S from Carnegie Mellon University, and a J.D. from Emory University School of Law.

Frank E. Thomas

Frank Thomas joined AMAG Pharmaceuticals, Inc. as Executive Vice President and Chief Financial Officer in August 2011. In November 2011, Mr. Thomas was appointed to the role of Chief Operating Officer of AMAG.

During his 19-year career, Mr. Thomas has held a variety of senior executive roles in the life sciences industry. From 2008 to 2011, Mr. Thomas served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, a medical diagnostics company focused on reproductive medicine where he established the company’s manufacturing, distribution and business processes in support of product development and commercialization. Prior to his time with Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., where he was promoted to President and Chief Executive Officer from the position of Senior Vice President and Chief Financial Officer to lead a turnaround effort, refocus the company on new product opportunities and improve operational execution. Mr. Thomas also served on the Board of Directors of Critical Therapeutics until 2008. Prior to 2004, he served as Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a development-stage biotechnology company focused on a cardiovascular product. Mr. Thomas’s prior positions include senior director of finance, corporate controller and audit roles with Mechanical Dynamics Inc., and Arthur Anderson LLP from 1992 to 2000, respectively. Since 2007, Mr. Thomas has been a member of the Board of Directors of the Massachusetts Biotechnology Council.

Mr. Thomas holds a B.B.A. in Business Administration from the University of Michigan, Ann Arbor.

Kathleen Weldon Tregoning

Kathleen W. Tregoning joined Biogen Idec as Vice President, Government Strategy in May 2006.  Her team is responsible for overseeing global government relations and public policy analysis for Biogen Idec out of the company’s office in Washington, D.C., focusing primarily on reimbursement, regulatory, and intellectual property policy issues.   

Prior to joining Biogen Idec, Ms. Tregoning was a professional staff member in the U.S. Congress, working for the chairmen of the House of Representatives Ways & Means Committee, the House Energy & Commerce Committee, and the Senate Budget Committee.  In these positions she was a key resource for members of Congress on a wide range of health care issues, including Medicare, Medicaid, prescription drugs, disease management, health care information technology, and post-acute care.  Ms. Tregoning was a lead staff member in the drafting of the Medicare Modernization Act of 2003 and the Deficit Reduction Act of 2005.  

Ms. Tregoning previously served as an Assistant Deputy Mayor for Policy and Budget for Mayor Richard Riordan in Los Angeles.  She began her career as a management consultant with Andersen Consulting, developing business strategies for clients across a range of industries.  She received her undergraduate degree in International Relations from Stanford University and her master’s degree in Public Policy from the Kennedy School of Government at Harvard University.   She lives in Virginia with her husband John and their two children. 

Charles Wilson, Ph.D.

Charles 'Chuck' Wilson, PhD serves as Vice President and Global Head of Strategic Alliances, leading the group responsible for externally oriented research at the Novartis Institutes for BioMedical Research (NIBR), the business unit of Novartis responsible for drug discovery and early clinical development. Partnering efforts include broad academic relationships to improve the understanding of basic disease processes, biotech collaborations focused on new drug discovery technologies, and in-licensing of compounds that have yet to reach clinical proof-of-concept.  Prior to joining Novartis, Chuck founded and led Archemix, a biotech company focused on the development of aptamers as therapeutics.  Responsible initially as its Chief Technology Officer for developing the company's technology platform and managing its drug discovery efforts, he moved into a business role focused on establishing partnerships with large pharma and biotech companies.  Before moving into industry, Chuck was an Associate Professor of Molecular, Cellular, and Developmental Biology at the University of California, Santa Cruz.  There he determined the first x-ray crystal structures of RNA aptamers bound to their targets.  Formally trained in structural biology and molecular biology, Chuck received his PhD from the University of California, San Francisco and his post-doctoral training in the Department of Molecular Biology at Massachusetts General Hospital.

Lawrence S. Wittenberg

Mr. Wittenberg, a partner in Goodwin Procter's Technology Companies Group and co-chair of its Life Sciences Practice, focuses his practice in matters involving life sciences. He joined Goodwin Procter in 2005.

Mr. Wittenberg has been an active participant in the life sciences industry since the mid-1980s, and his practice focuses exclusively on biotechnology and other life sciences companies. His clients range in size from start-ups to public companies, and he assists them with a full range of corporate and intellectual property transactions, including venture capital financings, public offerings, mergers and acquisitions, strategic alliances, joint ventures, licenses and technology transfer agreements, as well as with general legal and strategic advice.

Mr. Wittenberg also represents venture capital groups with respect to their investments in life sciences companies and investment banks in connection with public and private financings. He has structured and negotiated corporate partnering transactions with numerous world-wide pharmaceutical companies.

Prior to joining Goodwin Procter, Mr. Wittenberg was a partner in the Business Practice Group at Testa, Hurwitz & Thibeault, where he headed the Life Science Practice. Mr. Wittenberg holds a J.D. from Harvard Law School and a Bachelor's degree from Cornell University.

Robert Gottlieb

Robert Gottlieb, who is the Principal at the communications and strategy consulting firm, RMG Associates,  has more than 30 years of experience in the biotechnology and pharmaceutical industries as a consultant on strategy and communications, in-house communications director, and journalist.  

He has substantial experience and a strong track record in work with well over 100 companies and organizations ranging from start-ups in and outside of the U.S. to multi-nationals. Robert and RMG Associates bring particular expertise in corporate positioning, external and internal communications strategy, and preparation for financing and partnering.  He has helped more than 20 clients develop business plans to support venture and public financings.  

Robert co-founded Feinstein Kean Healthcare (now a division of Ogilvy Public Relations Worldwide), a Massachusetts-based communications and business consulting firm focused exclusively on biotechnology, pharmaceutical, and related healthcare organizations. Robert has been an active member of the biotechnology community in Massachusetts for more than 25 years. Robert served as an advisor to the Massachusetts Biotechnology Council for over 15 years. He also participates as a mentor in MIT’s Venture Mentoring Service and as a member of the Board of Directors of the New England Israel Business Council.

Previously, Robert directed press relations and corporate communications at Biogen Inc., during a period that laid the foundation for the company’s turnaround. He also managed communications for Biogen’s Research and Development Limited Partnership.

Prior to Biogen, Robert was executive editor of F-D-C Reports, “The Pink Sheet,” During his ten-years at “The Pink Sheet,” he covered the FDA and drug regulation, pharmaceutical business and the emergence of biotechnology as an industry.  He also founded a reference publication for the pharmaceutical and biotechnology industries, The NDA Pipeline, which has been published annually for more than 25 years.

Robert holds a B.A. degree from Trinity College (Connecticut).

William P. McDermott

Bill McDermott is a partner in the law firm of McDermott, Quilty & Miller LLP.  He specializes in state and federal relations in the government affairs and business strategies practice.  With a wealth of public and private sector experience, Bill's primary focus is on governmental relations, regulatory law and procurement for clients involved in biotechnology, health care, real estate development and technology-based industries.

Prior to joining the firm, Bill was a founding member of ML Strategies and attorney with the law firm of Mintz, Levin.  Bill was Senior Vice President of Government Affairs at ML/MLS from 1990-2000.  Among his accomplishments, Bill has successfully directed a number of major initiatives through the Massachusetts State Legislature, including the passage of the Economic Stimulus I and II bills, the Stem Cell bill and the $1B Life Sciences Initiative.

Bill's extensive experience in public service includes his appointment as Chief Counsel to the Massachusetts State Senate's Ways and Means Committee in 1988, and his appointment in 1983 as Undersecretary and General Counsel to the Executive Office of Economic Affairs for the Commonwealth of Massachusetts, where he completed his service as Acting Secretary.  Prior to returning to Massachusetts, Bill worked for the United States Congress in various capacities, including a position with Congressman Joe Moakley, former Chairman of the Rules Committee.

Bill has served as Legislative Counsel to the Massachusetts Biotechnology Council since 1994.

Bill received his Law Degree from American University and his Master's Degree in Public Administration from the John F. Kennedy School of Government at Harvard University.  He also completed graduate studies at Georgetown University and received his Bachelor's Degree from Boston College.  He is a member of the Massachusetts Bar.

About MassBio

MassBio is a not-for-profit organization committed to advancing the development of critical new science, technology and medicines that benefit people worldwide.

Founded in 1985, MassBio represents over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, and works to advance policy and promote education, while providing member programs and events, industry information, and services.

image of rss iconLatest Updates